The Oncogenic FOXL2 C134W Mutation Is a Key Driver of Granulosa Cell Tumors.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
18 01 2023
Historique:
received: 09 06 2022
revised: 24 10 2022
accepted: 15 11 2022
pubmed: 22 11 2022
medline: 20 1 2023
entrez: 21 11 2022
Statut: ppublish

Résumé

Adult-type granulosa cell tumors (AGCT) are the most common type of malignant ovarian sex cord-stromal tumors. Most AGCTs carry the somatic variant c.402C>G (p.C134W) affecting the transcription factor FOXL2. Germline dominant variants in FOXL2 are responsible for blepharophimosis syndrome, which is characterized by underdevelopment of the eyelid. In this work, we generated a mouse model harboring the C134W variant of FOXL2 to evaluate in vivo the poorly understood oncogenic role of FOXL2. The mutation was dominant regarding eyelid hypoplasia, reminiscent of blepharophimosis syndrome. Interestingly, Foxl2+/C134W female mice had reduced fertility and developed AGCTs through a progression from abnormal ovaries with aberrant granulosa cells to ovaries with stromal hyperplasia and atypia and on to tumors in adut mice. The genes dysregulated in mouse AGCTs exhibited the hallmarks of cancer and were consistent with a gain-of-function of the mutated allele affecting TGFβ signaling. A comparison of these data with previous results on human AGCTs indicated similar deregulated pathways. Finally, a mutational analysis of mouse AGCT transcriptomic data suggested the absence of additional driver mutations apart from FOXL2-C134W. These results provide a clear in vivo example in which a single mutational hit triggers tumor development associated with profound transcriptomic alterations. A newly generated mouse model carrying a FOXL2 mutation characteristic of adult-type granulosa cell tumors shows that FOXL2 C134W shifts the transcriptome towards a signature of granulosa cell cancer and drives tumorigenesis.

Identifiants

pubmed: 36409821
pii: 715073
doi: 10.1158/0008-5472.CAN-22-1880
doi:

Substances chimiques

Forkhead Transcription Factors 0
FOXL2 protein, human 0
Forkhead Box Protein L2 0
Foxl2 protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

239-250

Informations de copyright

©2022 American Association for Cancer Research.

Auteurs

Elena Llano (E)

Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biologıía Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Salamanca, Spain.
Departamento de Fisiología, Universidad de Salamanca, Salamanca, Spain.

Anne Laure Todeschini (AL)

Université Paris Cité, CNRS, Institut Jacques Monod, Paris, France.

Natalia Felipe-Medina (N)

Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biologıía Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Salamanca, Spain.

María D Corte-Torres (MD)

Instituto de Investigación Sanitaria de Asturias, Hospital Universitario del Principado de Asturias, Oviedo, Spain.

Yazmine B Condezo (YB)

Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biologıía Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Salamanca, Spain.

Manuel Sanchez-Martin (M)

Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain.

Sara López-Tamargo (S)

Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, Oviedo, Spain.

Aurora Astudillo (A)

Instituto de Investigación Sanitaria de Asturias, Hospital Universitario del Principado de Asturias, Oviedo, Spain.

Xose S Puente (XS)

Departamento de Bioquímica, Universidad de Oviedo, Oviedo, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Alberto M Pendas (AM)

Molecular Mechanisms Program, Centro de Investigación del Cáncer and Instituto de Biologıía Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Salamanca, Spain.

Reiner A Veitia (RA)

Université Paris Cité, CNRS, Institut Jacques Monod, Paris, France.
Université Paris Saclay, Paris, France.
Institut de Biologie François Jacob, CEA, Fontenay-aux-Roses, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH